

Johan W De Fijter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8653752/publications.pdf>

Version: 2024-02-01

114
papers

4,372
citations

109321

35
h-index

123424

61
g-index

114
all docs

114
docs citations

114
times ranked

5914
citing authors

#	ARTICLE	IF	CITATIONS
19	The Impact of Age on Rejection in Kidney Transplantation. <i>Drugs and Aging</i> , 2005, 22, 433-449.	2.7	61
20	Medication non-adherence after kidney transplantation: A critical appraisal and systematic review. <i>Transplantation Reviews</i> , 2020, 34, 100511.	2.9	61
21	Rationale and Design of the DIPAK 1 Study: A Randomized Controlled Clinical Trial Assessing the Efficacy of Lanreotide to Halt Disease Progression in Autosomal Dominant Polycystic Kidney Disease. <i>American Journal of Kidney Diseases</i> , 2014, 63, 446-455.	1.9	59
22	Safety of allogeneic bone marrow derived mesenchymal stromal cell therapy in renal transplant recipients: the neptune study. <i>Journal of Translational Medicine</i> , 2015, 13, 344.	4.4	59
23	Early Renal Ischemia-Reperfusion Injury in Humans Is Dominated by IL-6 Release from the Allograft. <i>American Journal of Transplantation</i> , 2009, 9, 1574-1584.	4.7	58
24	Pretransplantation Donor-Recipient Pair Seroreactivity Against BK Polyomavirus Predicts Viremia and Nephropathy After Kidney Transplantation. <i>American Journal of Transplantation</i> , 2017, 17, 161-172.	4.7	58
25	A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 601-615.	2.4	56
26	Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, i23-i26.	0.7	54
27	Severe COVID-19 in a renal transplant recipient: A focus on pharmacokinetics. <i>American Journal of Transplantation</i> , 2020, 20, 1896-1901.	4.7	51
28	Mesenchymal Stromal Cell Therapy for Solid Organ Transplantation. <i>Transplantation</i> , 2018, 102, 35-43.	1.0	47
29	Microvascular Damage in Type 1 Diabetic Patients Is Reversed in the First Year After Simultaneous Pancreas-Kidney Transplantation. <i>American Journal of Transplantation</i> , 2013, 13, 1272-1281.	4.7	46
30	The DESCARTES-Nantes survey of kidney transplant recipients displaying clinical operational tolerance identifies 35 new tolerant patients and 34 almost tolerant patients. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1002-1013.	0.7	46
31	Antibodies against ARHGDI1 are associated with long-term kidney graft loss. <i>American Journal of Transplantation</i> , 2019, 19, 3335-3344.	4.7	46
32	Rejection and function and chronic allograft dysfunction. <i>Kidney International</i> , 2010, 78, S38-S41.	5.2	44
33	Complement-mediated microangiopathy in IgA nephropathy and IgA vasculitis with nephritis. <i>Modern Pathology</i> , 2019, 32, 1147-1157.	5.5	43
34	Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease. <i>Gastroenterology</i> , 2019, 157, 481-491.e7.	1.3	42
35	Superior Long-term Survival for Simultaneous Pancreas-Kidney Transplantation as Renal Replacement Therapy: 30-Year Follow-up of a Nationwide Cohort. <i>Diabetes Care</i> , 2020, 43, 321-328.	8.6	42
36	Autologous bone marrow derived mesenchymal stromal cell therapy in combination with everolimus to preserve renal structure and function in renal transplant recipients. <i>Journal of Translational Medicine</i> , 2014, 12, 331.	4.4	41

#	ARTICLE	IF	CITATIONS
37	Dietary protein intake and kidney function decline after myocardial infarction: the Alpha Omega Cohort. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 106-115.	0.7	38
38	An old virtue to improve senior programs. <i>Transplant International</i> , 2009, 22, 259-268.	1.6	36
39	Estimation of Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease. <i>American Journal of Kidney Diseases</i> , 2015, 66, 792-801.	1.9	36
40	Salt, but not protein intake, is associated with accelerated disease progression in autosomal dominant polycystic kidney disease. <i>Kidney International</i> , 2020, 98, 989-998.	5.2	36
41	Effect of different types of statins on kidney function decline and proteinuria: a network meta-analysis. <i>Scientific Reports</i> , 2019, 9, 16632.	3.3	35
42	Human leukocyte antigen selected allogeneic mesenchymal stromal cell therapy in renal transplantation: The Neptune study, a phase I single-center study. <i>American Journal of Transplantation</i> , 2020, 20, 2905-2915.	4.7	34
43	Glycemic Stability Through Islet-After-Kidney Transplantation Using an Alemtuzumab-Based Induction Regimen and Long-Term Triple-Maintenance Immunosuppression. <i>American Journal of Transplantation</i> , 2016, 16, 246-253.	4.7	33
44	Allocation to highly sensitized patients based on acceptable mismatches results in low rejection rates comparable to nonsensitized patients. <i>American Journal of Transplantation</i> , 2019, 19, 2926-2933.	4.7	32
45	Toward a Sensible Single-antigen Bead Cutoff Based on Kidney Graft Survival. <i>Transplantation</i> , 2019, 103, 789-797.	1.0	31
46	Early Conversion to Prednisolone/Everolimus as an Alternative Weaning Regimen Associates With Beneficial Renal Transplant Histology and Function: The Randomized-Controlled MECANO Trial. <i>American Journal of Transplantation</i> , 2017, 17, 1020-1030.	4.7	29
47	Pancreas Transplantation With Grafts From Donors Deceased After Circulatory Death. <i>Transplantation</i> , 2018, 102, 333-339.	1.0	27
48	Local delivery of liposomal prednisolone leads to an anti-inflammatory profile in renal ischaemia-reperfusion injury in the rat. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 44-53.	0.7	26
49	The PROCARE consortium: Toward an improved allocation strategy for kidney allografts. <i>Transplant Immunology</i> , 2014, 31, 184-190.	1.2	25
50	Transplanting the elderly: Balancing aging with histocompatibility. <i>Transplantation Reviews</i> , 2015, 29, 205-211.	2.9	25
51	Acute Rejection After Kidney Transplantation Associates With Circulating MicroRNAs and Vascular Injury. <i>Transplantation Direct</i> , 2017, 3, e174.	1.6	25
52	Development and Validation of a Multiplex Non-HLA Antibody Assay for the Screening of Kidney Transplant Recipients. <i>Frontiers in Immunology</i> , 2018, 9, 3002.	4.8	25
53	Reduced Risk of BK Polyomavirus Infection in HLA-B51-positive Kidney Transplant Recipients. <i>Transplantation</i> , 2019, 103, 604-612.	1.0	25
54	Autologous bone marrow-derived mesenchymal stromal cell therapy with early tacrolimus withdrawal: The randomized prospective, single-center, open-label TRITON study. <i>American Journal of Transplantation</i> , 2021, 21, 3055-3065.	4.7	25

#	ARTICLE	IF	CITATIONS
55	Urinary TIMP-2 Predicts the Presence and Duration of Delayed Graft Function in Donation After Circulatory Death Kidney Transplant Recipients. <i>Transplantation</i> , 2019, 103, 1014-1023.	1.0	23
56	Reply to O.R. Colegio et al. <i>Journal of Clinical Oncology</i> , 2013, 31, 3298-3298.	1.6	21
57	Similar Reduction of Cytomegalovirus DNA Load by Oral Valganciclovir and Intravenous Ganciclovir on Pre-Emptive Therapy after Renal and Renal+Pancreas Transplantation. <i>Antiviral Therapy</i> , 2005, 10, 119-123.	1.0	21
58	Increased IL-10 production by stimulated whole blood cultures in primary IgA nephropathy. <i>Clinical and Experimental Immunology</i> , 1998, 111, 429-434.	2.6	20
59	Beneficial Immune Effects of Myeloid-Related Proteins in Kidney Transplant Rejection. <i>American Journal of Transplantation</i> , 2016, 16, 1441-1455.	4.7	20
60	Retrospective study on detection, treatment, and clinical outcome of graft thrombosis following pancreas transplantation. <i>Transplant International</i> , 2019, 32, 410-417.	1.6	20
61	Early remote ischaemic preconditioning leads to sustained improvement in allograft function after live donor kidney transplantation: long-term outcomes in the REal Protection Against Ischaemia+Reperfusion in transplantation (REPAIR) randomised trial. <i>British Journal of Anaesthesia</i> , 2019, 123, 584-591.	3.4	19
62	Kidney injury molecule-1 staining in renal allograft biopsies 10 days after transplantation is inversely correlated with functioning proximal tubular epithelial cells. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 2132-2141.	0.7	18
63	Transplanting the Elderly: Mandatory Age- and Minimal Histocompatibility Matching. <i>Frontiers in Immunology</i> , 2020, 11, 359.	4.8	18
64	A Comprehensive Evaluation of the Antibody-Verified Status of Eplets Listed in the HLA Epitope Registry. <i>Frontiers in Immunology</i> , 2021, 12, 800946.	4.8	18
65	Source and Relevance of the BK Polyomavirus Genotype for Infection After Kidney Transplantation. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz078.	0.9	17
66	A paired kidney analysis on the impact of pre-transplant anti-HLA antibodies on graft survival. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1056-1063.	0.7	17
67	Mechanisms and risk assessment of steroid resistance in acute kidney transplant rejection. <i>Transplant Immunology</i> , 2016, 38, 3-14.	1.2	16
68	Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study. <i>Drug Safety</i> , 2017, 40, 153-167.	3.2	16
69	Kidney injury biomarkers in an academic hospital setting: where are we now?. , 2019, 40, 79-97.		16
70	Urinary metabolites associate with the rate of kidney function decline in patients with autosomal dominant polycystic kidney disease. <i>PLoS ONE</i> , 2020, 15, e0233213.	2.5	16
71	How can we reduce costs of solid+phase multiplex+bead assays used to determine anti+HLA antibodies?. <i>Hla</i> , 2016, 88, 110-119.	0.6	15
72	Epidemiology and management of hypertension in paediatric and young adult kidney transplant recipients in The Netherlands. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1947-1956.	0.7	15

#	ARTICLE	IF	CITATIONS
73	Incidence and outcome of <scp>BK</scp> polyomavirus infection in a multicenter randomized controlled trial with renal transplant patients receiving cyclosporine, mycophenolate sodium, or everolimus-based low-dose immunosuppressive therapy. <i>Transplant Infectious Disease</i> , 2017, 19, e12687.	1.7	15
74	Urinary metabolites predict prolonged duration of delayed graft function in DCD kidney transplant recipients. <i>American Journal of Transplantation</i> , 2019, 19, 110-122.	4.7	15
75	High-urgency kidney transplantation in the Eurotransplant Kidney Allocation System: success or waste of organs? The Eurotransplant 15-year all-centre survey. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1515-1522.	0.7	14
76	Rational selection of a biomarker panel targeting unmet clinical needs in kidney injury. <i>Clinical Proteomics</i> , 2021, 18, 10.	2.1	14
77	Implementation of molecular matching in transplantation requires further characterization of both immunogenicity and antigenicity of individual HLA epitopes. <i>Human Immunology</i> , 2022, 83, 256-263.	2.4	14
78	Development and Provisional Validation of a Multiplex LC-MRM-MS Test for Timely Kidney Injury Detection in Urine. <i>Journal of Proteome Research</i> , 2021, 20, 5304-5314.	3.7	13
79	A case of mononucleosis infectiosa presenting with cholemic nephrosis. <i>CKJ: Clinical Kidney Journal</i> , 2011, 4, 170-172.	2.9	12
80	Safety and Efficacy Endpoints for Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients. <i>Journal of Immunology Research</i> , 2015, 2015, 1-14.	2.2	12
81	A pharmacological rationale for improved everolimus dosing in oncology and transplant patients. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1575-1586.	2.4	12
82	Low Birth Weight and Kidney Function in Middle-Aged Men and Women: The Netherlands Epidemiology of Obesity Study. <i>American Journal of Kidney Diseases</i> , 2019, 74, 751-760.	1.9	12
83	Model-informed precision dosing to optimise immunosuppressive therapy in renal transplantation. <i>Drug Discovery Today</i> , 2021, 26, 2527-2546.	6.4	12
84	Exploring genetic and non-genetic risk factors for delayed graft function, acute and subclinical rejection in renal transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 227-237.	2.4	11
85	Cardiovascular Risk Factors Accelerate Kidney Function Decline in Post-Myocardial Infarction Patients: The Alpha Omega Cohort Study. <i>Kidney International Reports</i> , 2018, 3, 879-888.	0.8	10
86	Presence of intragraft B cells during acute renal allograft rejection is accompanied by changes in peripheral blood B cell subsets. <i>Clinical and Experimental Immunology</i> , 2019, 196, 403-414.	2.6	10
87	Diabetic nephropathy alters circulating long noncoding RNA levels that normalize following simultaneous pancreas-kidney transplantation. <i>American Journal of Transplantation</i> , 2020, 20, 3451-3461.	4.7	10
88	Serum Potassium and Mortality Risk in Hemodialysis Patients: A Cohort Study. <i>Kidney Medicine</i> , 2021, 4, 100379.	2.0	10
89	Body-fat indicators and kidney function decline in older post-myocardial infarction patients: The Alpha Omega Cohort Study. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 90-99.	1.8	9
90	Early Steroid Withdrawal Compared With Standard Immunosuppression in Kidney Transplantation - Interim Analysis of the Amsterdam-Leiden-Groningen Randomized Controlled Trial. <i>Transplantation Direct</i> , 2018, 4, e354.	1.6	9

#	ARTICLE	IF	CITATIONS
91	No Apparent Influence of Nonadherence on Tacrolimus Inpatient Variability in Stable Kidney Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 702-709.	2.0	8
92	Circulating Long Noncoding RNA LNC-EPHA6 Associates with Acute Rejection after Kidney Transplantation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5616.	4.1	8
93	T-Cell Epitopes Shared Between Immunizing HLA and Donor HLA Associate With Graft Failure After Kidney Transplantation. <i>Frontiers in Immunology</i> , 2021, 12, 784040.	4.8	8
94	HLA-DQ-Specific Recombinant Human Monoclonal Antibodies Allow for In-Depth Analysis of HLA-DQ Epitopes. <i>Frontiers in Immunology</i> , 2021, 12, 761893.	4.8	8
95	Effect of initial immunosuppression on long-term kidney transplant outcome in immunological low-risk patients. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1417-1422.	0.7	7
96	Biopsy-Controlled Non-Invasive Quantification of Collagen Type VI in Kidney Transplant Recipients: A Post-Hoc Analysis of the MECANO Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 3216.	2.4	7
97	Model-Informed Precision Dosing of Everolimus: External Validation in Adult Renal Transplant Recipients. <i>Clinical Pharmacokinetics</i> , 2021, 60, 191-203.	3.5	7
98	Counselling the elderly between hope and reality. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2079-2081.	0.7	6
99	Elevated intragraft expression of innate immunity and cell death-related markers is a risk factor for adverse graft outcome. <i>Transplant Immunology</i> , 2018, 48, 39-46.	1.2	5
100	Model-Based Estimation of Iohexol Plasma Clearance for Pragmatic Renal Function Determination in the Renal Transplantation Setting. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1201-1215.	3.5	5
101	Recurrence of glomerulonephritis: an underestimated and unmet medical need. <i>Kidney International</i> , 2017, 92, 294-296.	5.2	4
102	Epidemiology and management of hypertension in paediatric and young adult kidney transplant recipients in The Netherlands. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 402-402.	0.7	3
103	Urinary Tissue Inhibitor of Metalloproteinases-2 and Insulin-Like Growth Factor Binding Protein 7 Do Not Correlate With Disease Severity in ADPKD Patients. <i>Kidney International Reports</i> , 2019, 4, 833-841.	0.8	3
104	Multiplex LC-MS/MS Testing for Early Detection of Kidney Injury: A Next-Generation Alternative to Conventional Immunoassays?. <i>Journal of Applied Laboratory Medicine</i> , 2022, 7, 923-930.	1.3	3
105	Cardiovascular Effects of Autologous Bone Marrow-Derived Mesenchymal Stromal Cell Therapy With Early Tacrolimus Withdrawal in Renal Transplant Recipients: An Analysis of the Randomized TRITON Study. <i>Journal of the American Heart Association</i> , 2021, 10, e023300.	3.7	3
106	Efficacy and safety of selective decontamination of the digestive tract (SDD) to prevent recurrent hepatic cyst infections in polycystic liver disease: a retrospective case series. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2666-2669.	3.0	2
107	The Authors Reply:. <i>Kidney International</i> , 2014, 85, 713-714.	5.2	1
108	Skin disorders indicating peripheral arterial occlusive disease and chronic venous insufficiency in organ transplant recipients. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107623.	2.3	1

#	ARTICLE	IF	CITATIONS
109	Tacrolimus Dosing in Mycophenolate-Treated Patientsâ€”Can We Get Away With Less?. <i>Transplantation</i> , 2011, 92, 10-11.	1.0	0
110	SaO003USE OF THIAZIDE DIURETICS DOES NOT WORSEN DISEASE PROGRESSION IN ADPKD. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.7	0
111	SP011URINARY ALANINE/CITRATE RATIO ASSOCIATES WITH THE RATE OF EGFR DECLINE IN PATIENTS WITH ADPKD. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.7	0
112	HLA-B51 Reduces Risk of BK Polyomavirus Viremia After Kidney Transplantation. <i>Transplantation</i> , 2019, 103, e386-e387.	1.0	0
113	Single antigen testing to reduce early antibody-mediated rejection risk in female recipients of a spousal donor kidney. <i>Transplant Immunology</i> , 2021, 67, 101407.	1.2	0
114	Diabetic nephropathy and beta-cell replacement therapy. <i>Netherlands Journal of Medicine</i> , 2004, 62, 71-5.	0.5	0